T1	Claim 188 273	In recent years, encouraging results of preoperative radiotherapy have been reported.
T2	Claim 90 187	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
T4	Premise 1841 1962	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
T5	Premise 1964 2164	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
T6	Premise 2165 2324	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
T7	Premise 2325 2746	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
T8	Claim 2747 2796	The patient accrual of our trial is satisfactory,
T9	Claim 2797 2898	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
R1	Support Arg1:T4 Arg2:T9	
R2	Support Arg1:T5 Arg2:T9	
R3	Support Arg1:T6 Arg2:T9	
R4	Support Arg1:T7 Arg2:T9	
